Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & CFO | March 05, 2019 | March 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Jazz Pharmaceuticals plc
Report date March 05, 2019 · Filed March 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 36,200 |
Ending reported balance
After 2019-03-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-05 · Tax withholding · Disposed 1,267 · Balance 38,700 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Row 2 · 2019-03-05 · Tax withholding · Disposed 1,348 · Balance 37,352 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Row 3 · 2019-03-06 · Sale · Disposed 1,152 · Balance 36,200 F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PRA Health Sciences, Inc.
Report date July 01, 2021 · Filed July 01, 2021
Section 16 reporting ended · disclosed 2021-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-01 transaction · row 1
1 source rowRow 1 · 2021-07-01 · Disposition to issuer · Disposed 7,127 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration"). F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the "Merger Agreement"), dated as of February 24, 2021, by and among the Issuer, ICON plc ("ICON"), ICON US Holdings Inc. ("US HoldCo") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the "Merger Consideration").
F2: Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,016 | $144.96 | $147,280.38 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,690 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.3100 to $145.2600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,253 | $147.44 | $332,182.32 |
DisclosureSEC source: 0001232524-18-000032 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,706 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:05 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 700 | $152.16 | $106,512.00 |
DisclosureSEC source: 0001601583-18-000002 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,959 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 62 ordinary shares acquired on May 31, 2017 and 64 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:05 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 5,115 | $79.90 | $408,688.50 |
DisclosureSEC source: 0001104659-17-069448 · a4.xml · nonDerivative · entry 3 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $79.85 to $79.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2017 Filed Nov 17, 2017 21:05 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GiftCommon Stock | 5,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-069448 · a4.xml · nonDerivative · entry 2 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 5,115 Read SEC document |
| November 14, 2017 Filed Nov 17, 2017 21:05 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GiftCommon Stock | 5,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-069448 · a4.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,810 Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 20:05 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantCommon Stock | 1,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-045047 · a4.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,925 F1 · kind: Represents a grant of restricted stock which will vest fifty percent on each of the first two anniversaries of the grant date, subject to continued service on such dates. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 18:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001140361-17-025792 · doc1.xml · derivative · entry 1 Young Matthew P. · CIK 0001601583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 815 | $153.79 | $125,338.85 |
DisclosureSEC source: 0001232524-17-000117 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,533 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| May 03, 2017 Filed May 5, 2017 20:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,565 | $158.38 | $247,864.70 |
DisclosureSEC source: 0001601583-17-000003 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,348 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,266 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000064 · edgardoc.xml · derivative · entry 3 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 Underlying: Ordinary Shares · 24,266 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 734 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000064 · edgardoc.xml · derivative · entry 2 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Ordinary Shares · 734 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 7, 2017 00:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000064 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,913 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,994 | $136.97 | $273,118.18 |
DisclosureSEC source: 0001232524-17-000039 · edgardoc.xml · nonDerivative · entry 1 Young Matthew P. · CIK 0001601583 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,913 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 39 ordinary shares acquired on May 31, 2016 and 59 ordinary shares acquired on November 30, 2016 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.